← Eichor
Study identifier: NCT06947512 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Personalization of Visual Characters and Text-to-Speech (TTS) to Support Learning in Students With Reading Difficulties

Condition: Developmental Dyslexia · Reading Problem  ·  Sponsor: IRCCS Eugenio Medea

PhaseNA
Planned participants90
Who can joinAll sexes, 7 Years to 15 Years
Healthy volunteersYes

About this study

Previous research has shown the importance of font type, size and spacing to facilitate text reading in dyslexia. A special automatized procedure was designed to select the most favorable parameters for both text visualization and text-to-speech (TTS) conversion to be used by students with reading difficulties. The validation of its outcomes will be carried out through a systematic comparison of the use of the personalized versus standard fonts and voices in reading and writing tests.

This description comes directly from the study's public registry record.

Talk to the study team

Maria Luisa Lorusso, Ph.D  ·  031-877592  ·  marialuisa.lorusso@lanostrafamiglia.it

Always discuss trial participation with your own doctor first.

Locations (3)

IRCCS E. Medea, polo di Bosisio PariniBosisio Parini, LC, ItalyRecruiting
IRCCS E.Medea, polo di ConeglianoConegliano, TV, ItalyRecruiting
Associazione La Nostra FamigliaTreviso, TV, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06947512